الفهرس 
multiple myelomaOnly 14 pages are availabe for public view
 |  | from | 85 |  |  |
| | | from | 85 | | |
Abstract
Introduction: Multiple myeloma is one of the commonest hematological neoplasms. Auto stem cell transplantation is still the standard plan of care as consolidation in fit eligible patients after receiving induction chemotherapy.
Aim of the work: This research aims to explore the significance and validity of ADAMTS-13 activity to predict the prognosis (outcome, disease free survival) and complications (including transplant related mortality, relapse) of multiple myeloma patients with a low or normal activity of ADAMTS-13 before auto bone marrow transplantation.
Patients and Methods: In this prospective Cohort study, pre transplantation plasma level of ADMATS13 was studied for its potential effect on the outcome. The study was done in a single bone marrow transplantation facility and included 51 patients previously diagnosed with MM, received induction chemotherapy, and admitted for ASCT.
Results: Blood samples were collected prior to transplantation and the patients were followed up throughout the transplantation process and till 12 months after transplantation. ADAMTS-13 levels came between 24.6% and 152.4%. The average level was 74.78%, with half of patients below 64.77%. 12 out of 51 patients (23.5%) had low ADAMTS-13 level below 50%. 44 out of 51 patients (86.3%) survived though the follow up period without any evidence of relapse. Only 7 patients (13.7%) had MM relapse and none of the patients died of non-relapse causes related to transplantation.
Conclusion: The pre transplantation plasma level of ADAMTS-13 has no statistically significant effect on the outcome, relapse incidence or disease free survival during the first 12 months after transplantation.